Korsinczky Michael L J, Schirra Horst Joachim, Craik David J
Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
Curr Protein Pept Sci. 2004 Oct;5(5):351-64. doi: 10.2174/1389203043379594.
SFTI-1 is a bicyclic 14 amino acid peptide that was originally isolated from the seeds of the sunflower Helianthus annuus. It is a potent inhibitor of trypsin, with a sub-nanomolar K(i) value and is homologous to the active site region of the well-known family of serine protease inhibitors known as the Bowman-Birk trypsin inhibitors. It has a cyclic backbone that is cross-braced by a single disulfide bridge and a network of hydrogen bonds that result in a well-defined structure. SFTI-1 is amenable to chemical synthesis, allowing for the creation of synthetic variants. Alterations to the structure such as linearising the backbone or removing the disulfide bridge do not reduce the potency of SFTI-1 significantly, and minimising the peptide to as few as nine residues results in only a small decrease in reactivity. The creation of linear variants of SFTI-1 also provides a tool for investigating putative linear precursor peptides. The mechanism of biosynthesis of SFTI-1 is not yet known but it seems likely that it is a gene-coded product that has arisen from a precursor protein that may be evolutionarily related to classic Bowman-Birk inhibitors.
SFTI-1是一种双环14氨基酸肽,最初从向日葵种子中分离得到。它是一种有效的胰蛋白酶抑制剂,解离常数(K(i))值低于纳摩尔,与著名的丝氨酸蛋白酶抑制剂家族Bowman-Birk胰蛋白酶抑制剂的活性位点区域同源。它具有由单个二硫键交叉支撑的环状骨架和导致明确结构的氢键网络。SFTI-1适合化学合成,可用于创建合成变体。对结构的改变,如使骨架线性化或去除二硫键,不会显著降低SFTI-1的效力,将肽最小化至仅九个残基只会导致反应性略有下降。SFTI-1线性变体的产生也为研究假定的线性前体肽提供了一种工具。SFTI-1的生物合成机制尚不清楚,但它似乎可能是一种基因编码产物,源自可能与经典Bowman-Birk抑制剂在进化上相关的前体蛋白。